Our mission: find solutions for hearing disorders

We are developing treatments which could revolutionize the care of patients with inner ear disorders

Our approach

A relentless search for innovation

Sensorion’s mission is to offer innovative therapeutic solutions providing long-term improvements to people living with, or at risk of, inner ear disorders. Sensorion’s portfolio of solutions to unmet medical and social needs in inner ear disorders rests on three pillars – Restore, Treat, Prevent.

Restore

We aim to restore hearing by treating genetic diseases previously regarded as untreatable.

Treat

We aim to treat hearing disorders through innovative small molecule therapeutic solutions.

Prevent

We aim to prevent non-genetic hearing loss (e.g drug or surgery-related) through targeted therapeutic programs.

Investors

A clear strategy around our 3 pillars - Restore, Treat, Prevent

With our partners, Sensorion is committed to building and developing a cutting-edge therapeutic portfolio for major causes of hearing loss.

More information

Discover our corporate presentation

Sensorion focuses on innovative treatments that can restore, treat and prevent hearing loss.

Download our corporate presentation

NEWS & EVENTS

Discover our latest news

Our partners

Career

The beginning of a great journey

Engineer Process Development USP/DSP F/M

Entreprise Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its […]

Discover
Senior Program Manager – Pharmaceutical Development F/M

Entreprise Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its […]

Discover